Fed Chair Kevin Warsh’s move to dial back forward guidance has left markets more data driven and, at times, more jumpy. When rate clues are harder to read, many investors start to focus on stocks that have shown relatively low price swings and steadier profiles. That is where a low volatility screener can help filter the chaos. This article looks at three stocks from that list that appear positively exposed to the current policy uncertainty and recent volatility in Treasury yields, and explains why they might matter for a portfolio that aims to keep risk more contained.

Boston Scientific (BSX)

Overview: Boston Scientific is a large US medical device company that supplies minimally invasive products for cardiology, endoscopy, urology, neuromodulation and other interventional procedures used in hospitals and clinics worldwide.

Market Cap: US$68.5b

Boston Scientific stands out in a choppy rate backdrop because it couples a broad, procedure driven device portfolio with relatively low share price volatility, which can appeal when investors are nervous about Fed policy signals. Earnings growth has recently been strong, supported by higher margins and contributions from acquired assets in cardiology and neuromodulation, while analysts still expect steady, if not spectacular, growth ahead. At the same time, product recalls, Watchman reimbursement and workflow pressure, and a large cost reduction program that includes headcount cuts underline that execution and regulatory risk are real. If you are looking for a large cap healthcare stock that mixes resilience with some growth optionality, Boston Scientific is worth a closer look.

Boston Scientific’s steady earnings profile and broad device portfolio could be masking a bigger story about quality and resilience. Before you decide how it fits your plan, review the analysis report for Boston Scientific

Cochlear (ASX:COH)

Overview: Cochlear develops and sells implantable hearing systems that help children and adults with moderate to profound hearing loss, ranging from cochlear implants and bone conduction devices to sound processors and accessories used in everyday life.

Operations: Cochlear generates A$2.3b in revenue primarily from implantable hearing devices, with sales spread across the Americas, EMEA and Asia Pacific regions.

Market Cap: A$8.0b

Cochlear can attract investors seeking lower volatility because it combines a global hearing implant franchise and recurring revenue from upgrades with a record of premium products such as the newly cleared Osia 3 processor. At the same time, the company is addressing softer implant demand in developed markets, pricing and reimbursement pressure, and earnings that recently declined while margins eased from 16% to 14.8%. Analysts have highlighted modest earnings growth expectations and note valuation support, even after recent downgrades. If you want to understand how that mix of product strength, demographic trends and margin risk compares with today’s uncertainty over Fed policy and bond yields, the analysis report for Cochlear provides further detail.

Momentum in Cochlear’s premium hearing implants and upgrades might be masking a bigger valuation story. See how current pricing, earnings pressure and product strength line up in the analysis report for Cochlear

Fisher & Paykel Healthcare (NZSE:FPH)

Overview: Fisher & Paykel Healthcare is a New Zealand based medical device company that designs and sells respiratory care systems, humidification products and obstructive sleep apnea equipment used in hospitals and homes across North America, Europe, Asia Pacific and other regions.

Operations: Fisher & Paykel Healthcare generates NZ$2.3b in revenue from respiratory products, with around NZ$1.1b from North America, NZ$620.1m from Europe, NZ$476.1m from Asia Pacific and NZ$106.1m from other regions.

Market Cap: NZ$24.5b

Fisher & Paykel Healthcare can appeal to low volatility focused investors because it operates in a core area of hospital and home respiratory care where demand is often steady through the cycle. The company has been growing sales and earnings while maintaining high quality margins and returns on equity. At the same time, investors need to weigh that relatively resilient profile against an expensive P/E, pressure on hospital budgets, tariffs on exported products and competition in respiratory and sleep apnea masks that could affect future pricing power. For those considering whether a global, dividend paying device company with strong recent earnings momentum but a full valuation fits their risk profile in a more data driven Fed era, Fisher & Paykel Healthcare may warrant closer review.

Fisher & Paykel Healthcare’s strong respiratory foothold and high margins could be hiding a crucial piece of the story. For the full picture, read the analysis report for Fisher & Paykel Healthcare to see what might shift next.

The three stocks highlighted here are just a starting point. The full low volatility screen surfaces 32 more companies with similarly detailed stories that can round out your watchlist in different sectors through the Low Volatility Stocks screener. Use Simply Wall St to identify and analyze the specific catalysts, financial health traits and narratives that fit your own risk tolerance so you can focus on the highest conviction ideas in this low volatility space.

Take Control of Your Investment Journey

If Cochlear or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Curious About What Else You Might Be Missing

Fresh ideas often move first when momentum builds, and slow research can end up chasing breakouts or dropping stories. Scan these under the radar lists now to review potential opportunities at an earlier stage.

• Scan our curated group of 9 dividend fortresses to identify income-focused candidates that may help keep portfolios steadier while rates shift.
• Review 26 quantum computing stocks to see where the next developments in computing could emerge, as demand for advanced processing power evolves.
• Check 34 power grid technology and infrastructure stocks for companies positioned around critical infrastructure and transmission technology as grid upgrade themes develop.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.